Vera Therapeutics logo

Vera Therapeutics

VERA | NASDAQ
Chart Builder DCF Calculator
$26.97
-$1.13 (-4.02%)
At close: Nov 16, 2026, 4:00 PM ET
$26.85
-$0.12 (-0.44%)
After-hours: Nov 16, 2026, 7:30 PM ET
-4.02%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
43.2
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #441/1021 (Top 43%)

Key Statistics

Market Data

Market Cap $1.95B
1D Range
26.86 28.17
52W Range
26.74 55.67

Valuation (TTM)

PE -4.57
PB 5.85
EV/EBITDA -4.04

Valuation (NTM)

Forward PE N/A
Forward PEG -0.17
Price Target $87.00
Loading financial charts...

Profile

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United St...

Sector Healthcare
Industry Biotechnology
Employees 361
IPO Date May 14, 2021
Website veratx.com
Fiscal Year January - December

Latest News

He Takes a New Job at 64 With a $100,000 Stock Grant. When the Shares Vest, Social Security Could Withhold His Retirement Checks Even Though He Hasn’t Sold a Single Share

4 days ago · 247wallst.com

He Takes a New Job at 64 With a $100,000 Stock Grant. When the Shares Vest, Social Security Could Withhold His Retirement Checks Even Though He Hasn’t Sold a Single Share
Vera Therapeutics Q3 Earnings Call Highlights

10 days ago · marketbeat.com

Vera Therapeutics Q3 Earnings Call Highlights
Vera Therapeutics, Inc. (VERA) Q3 2026 Earnings Call Transcript

11 days ago · seekingalpha.com

Vera Therapeutics, Inc. (VERA) Q3 2026 Earnings Call Transcript
Vera Therapeutics, Inc. (VERA) Reports Q3 Loss, Tops Revenue Estimates

11 days ago · zacks.com

Vera Therapeutics, Inc. (VERA) Reports Q3 Loss, Tops Revenue Estimates
Vera Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference

15 days ago · globenewswire.com

Vera Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
Vera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy Results

25 days ago · marketbeat.com

Vera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy Results
Vera Therapeutics, Inc. (VERA) Discusses Final Efficacy Results of ORIGIN Phase III Trial of Atacicept in IgA Nephropathy Transcript

25 days ago · seekingalpha.com

Vera Therapeutics, Inc. (VERA) Discusses Final Efficacy Results of ORIGIN Phase III Trial of Atacicept in IgA Nephropathy Transcript
Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine

26 days ago · globenewswire.com

Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine
Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast

28 days ago · globenewswire.com

Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026

2 months ago · globenewswire.com

Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026

Earnings

Latest Earnings
Nov 5, 2026
EPS
-$1.3
Beat +19.75%
REV
$10.28M
Beat +200.37%
Next Earnings
Feb 25, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
9
Consensus
Buy
Price Target
$76.50
Upside
+183.65%
Buy (8)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.